Yayın: Biologic agents in psoriasis
Tarih
Kurum Yazarları
Başkan, Emel Bülbül
Yazarlar
Danışman
Dil
Türü
Yayıncı:
Vakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Özet
Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.
Açıklama
Kaynak:
Anahtar Kelimeler:
Konusu
Dermatology, Adalimumab, Biologics, Efalizumab, Etanercept, Infliximab, Psoriasis, Chronic plaque psoriasis, Randomized controlled-trial, Patient-reported outcomes, Long-term, treatment, Phase-III, Double-blind, Efalizumab therapy, Rheumatoid-arthritis, Open-label, Infliximab monotherapy
Alıntı
Başkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50